US equities
|
SPCX
$147.79
▲+0.00%
NVDA
$216.47
▲+0.00%
MU
$896.07
▲+0.00%
TSLA
$373.71
▲+0.00%
SNDK
$1,365.38
▲+0.00%
GOOGL
$340.27
▲+0.00%
NFLX
$68.69
▲+0.00%
AMD
$534.74
▲+0.00%
SPCX
$147.79
▲+0.00%
NVDA
$216.47
▲+0.00%
MU
$896.07
▲+0.00%
TSLA
$373.71
▲+0.00%
SNDK
$1,365.38
▲+0.00%
GOOGL
$340.27
▲+0.00%
NFLX
$68.69
▲+0.00%
AMD
$534.74
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Epicrispr Biotechnologies
Epicrispr Biotechnologies Appoints Enoch Kariuki, PharmD, to Board of Directors
October 20, 2026
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Biotechnologies Awarded $8 Million CIRM Grant to Advance EPI-321 for FSHD
October 19, 2026
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Reports Positive Six-Month Data at The World Muscle Society Meeting Demonstrating Increased Lean Muscle Volume and Muscle Strength in FSHD Patients Treated with EPI-321
October 05, 2026
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD
August 11, 2026
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Completes Enrollment and Dose Escalation in First-in-Human EPI-321 Trial for FSHD
July 07, 2026
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321
June 27, 2026
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Biotechnologies Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
March 24, 2026
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Reports Early Clinical Activity and Favorable Safety Profile in First-in-Human Epigenetic Editing Study for FSHD
January 08, 2026
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Biotechnologies to Present at 44th Annual J.P. Morgan Healthcare Conference
December 08, 2025
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Biotechnologies Doses First Patient in First-in-Human Clinical Trial of EPI-321 for Facioscapulohumeral Muscular Dystrophy
August 05, 2025
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Biotechnologies Named Finalist in XPRIZE Healthspan Competition FSHD Bonus Prize
May 12, 2025
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual Meeting
May 05, 2025
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study
April 23, 2025
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
April 03, 2025
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD
March 26, 2025
From
Epicrispr Biotechnologies
Via
Business Wire
Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT
October 22, 2024
From
Epicrispr Biotechnologies
Via
GlobeNewswire
